抗精神病药物对急性精神分裂症患者的长期疗效:系统评价和网络荟萃分析。

IF 73.3 1区 医学 Q1 Medicine
World Psychiatry Pub Date : 2023-06-01 DOI:10.1002/wps.21089
Stefan Leucht, Johannes Schneider-Thoma, Angelika Burschinski, Natalie Peter, Dongfang Wang, Shimeng Dong, Maximilian Huhn, Adriani Nikolakopoulou, Georgia Salanti, John M Davis
{"title":"抗精神病药物对急性精神分裂症患者的长期疗效:系统评价和网络荟萃分析。","authors":"Stefan Leucht,&nbsp;Johannes Schneider-Thoma,&nbsp;Angelika Burschinski,&nbsp;Natalie Peter,&nbsp;Dongfang Wang,&nbsp;Shimeng Dong,&nbsp;Maximilian Huhn,&nbsp;Adriani Nikolakopoulou,&nbsp;Georgia Salanti,&nbsp;John M Davis","doi":"10.1002/wps.21089","DOIUrl":null,"url":null,"abstract":"<p><p>Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of antipsychotic drugs in acutely ill patients using network meta-analysis. We searched the Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded trials of at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change in overall symptoms of schizophrenia; secondary outcomes were all-cause discontinuation; change in positive, negative and depressive symptoms; quality of life, social functioning, weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and sedation. Confidence in the results was assessed by the CINeMA (Confidence in Network Meta-Analysis) framework. We included 45 studies with 11,238 participants. In terms of overall symptoms, olanzapine was on average more efficacious than ziprasidone (standardized mean difference, SMD=0.37, 95% CI: 0.26-0.49), asenapine (SMD=0.33, 95% CI: 0.21-0.45), iloperidone (SMD=0.32, 95% CI: 0.15-0.49), paliperidone (SMD=0.28, 95% CI: 0.11-0.44), haloperidol (SMD=0.27, 95% CI: 0.14-0.39), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (SMD=0.16, 95% CI: 0.04-0.28) and risperidone (SMD=0.12, 95% CI: 0.03-0.21). The 95% CIs for olanzapine versus aripiprazole and risperidone included the possibility of trivial effects. The differences between olanzapine and lurasidone, amisulpride, perphenazine, clozapine and zotepine were either small or uncertain. These results were robust in sensitivity analyses and in line with other efficacy outcomes and all-cause discontinuation. Concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compared to amisulpride. Our data suggest that olanzapine is more efficacious than a number of other antipsychotic drugs in the longer term, but its efficacy must be weighed against its side effect profile.</p>","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":null,"pages":null},"PeriodicalIF":73.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168166/pdf/WPS-22-315.pdf","citationCount":"2","resultStr":"{\"title\":\"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.\",\"authors\":\"Stefan Leucht,&nbsp;Johannes Schneider-Thoma,&nbsp;Angelika Burschinski,&nbsp;Natalie Peter,&nbsp;Dongfang Wang,&nbsp;Shimeng Dong,&nbsp;Maximilian Huhn,&nbsp;Adriani Nikolakopoulou,&nbsp;Georgia Salanti,&nbsp;John M Davis\",\"doi\":\"10.1002/wps.21089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of antipsychotic drugs in acutely ill patients using network meta-analysis. We searched the Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded trials of at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change in overall symptoms of schizophrenia; secondary outcomes were all-cause discontinuation; change in positive, negative and depressive symptoms; quality of life, social functioning, weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and sedation. Confidence in the results was assessed by the CINeMA (Confidence in Network Meta-Analysis) framework. We included 45 studies with 11,238 participants. In terms of overall symptoms, olanzapine was on average more efficacious than ziprasidone (standardized mean difference, SMD=0.37, 95% CI: 0.26-0.49), asenapine (SMD=0.33, 95% CI: 0.21-0.45), iloperidone (SMD=0.32, 95% CI: 0.15-0.49), paliperidone (SMD=0.28, 95% CI: 0.11-0.44), haloperidol (SMD=0.27, 95% CI: 0.14-0.39), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (SMD=0.16, 95% CI: 0.04-0.28) and risperidone (SMD=0.12, 95% CI: 0.03-0.21). The 95% CIs for olanzapine versus aripiprazole and risperidone included the possibility of trivial effects. The differences between olanzapine and lurasidone, amisulpride, perphenazine, clozapine and zotepine were either small or uncertain. These results were robust in sensitivity analyses and in line with other efficacy outcomes and all-cause discontinuation. Concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compared to amisulpride. Our data suggest that olanzapine is more efficacious than a number of other antipsychotic drugs in the longer term, but its efficacy must be weighed against its side effect profile.</p>\",\"PeriodicalId\":23858,\"journal\":{\"name\":\"World Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":73.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168166/pdf/WPS-22-315.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/wps.21089\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wps.21089","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

大多数针对精神分裂症的急性期抗精神病药物试验只持续几周,但患者通常必须服用这些药物更长时间。我们使用网络荟萃分析检验了抗精神病药物对急性病人的长期疗效。我们检索了Cochrane精神分裂症组注册到2022年3月6日的随机、盲法试验,所有第二代抗精神病药物和18种第一代抗精神病药物至少持续6个月。主要结局是精神分裂症总体症状的改变;次要结局为全因停药;阳性、阴性和抑郁症状的变化;生活质量、社会功能、体重增加、抗帕金森药物使用、静坐症、血清催乳素水平、QTc延长和镇静。研究结果的可信度由CINeMA(网络元分析可信度)框架评估。我们纳入了45项研究,11,238名参与者。就总体症状而言,奥氮平的平均疗效优于齐拉西酮(标准化平均差异,SMD=0.37, 95% CI: 0.26-0.49)、阿西那平(SMD=0.33, 95% CI: 0.21-0.45)、伊哌啶酮(SMD=0.32, 95% CI: 0.15-0.49)、帕利哌酮(SMD=0.28, 95% CI: 0.11-0.44)、氟哌啶醇(SMD=0.27, 95% CI: 0.14-0.39)、喹硫平(SMD=0.25, 95% CI: 0.12-0.38)、阿立哌唑(SMD=0.16, 95% CI: 0.04-0.28)和利培酮(SMD=0.12, 95% CI: 0.03-0.21)。奥氮平与阿立哌唑和利培酮的95% ci包括轻微影响的可能性。奥氮平与鲁拉西酮、氨硫pride、哌那嗪、氯氮平和佐替平的差异很小或不确定。这些结果在敏感性分析中是稳健的,与其他疗效结果和全因停药一致。关于体重增加,奥氮平的影响高于所有其他抗精神病药物,与齐拉西酮相比,其平均差异为-4.58 kg (95% CI: -5.33至-3.83),与氨硫pride相比,其平均差异为-2.30 kg (95% CI: -3.35至-1.25)。我们的数据表明,从长期来看,奥氮平比其他一些抗精神病药物更有效,但其疗效必须与其副作用进行权衡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.

Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of antipsychotic drugs in acutely ill patients using network meta-analysis. We searched the Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded trials of at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change in overall symptoms of schizophrenia; secondary outcomes were all-cause discontinuation; change in positive, negative and depressive symptoms; quality of life, social functioning, weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and sedation. Confidence in the results was assessed by the CINeMA (Confidence in Network Meta-Analysis) framework. We included 45 studies with 11,238 participants. In terms of overall symptoms, olanzapine was on average more efficacious than ziprasidone (standardized mean difference, SMD=0.37, 95% CI: 0.26-0.49), asenapine (SMD=0.33, 95% CI: 0.21-0.45), iloperidone (SMD=0.32, 95% CI: 0.15-0.49), paliperidone (SMD=0.28, 95% CI: 0.11-0.44), haloperidol (SMD=0.27, 95% CI: 0.14-0.39), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (SMD=0.16, 95% CI: 0.04-0.28) and risperidone (SMD=0.12, 95% CI: 0.03-0.21). The 95% CIs for olanzapine versus aripiprazole and risperidone included the possibility of trivial effects. The differences between olanzapine and lurasidone, amisulpride, perphenazine, clozapine and zotepine were either small or uncertain. These results were robust in sensitivity analyses and in line with other efficacy outcomes and all-cause discontinuation. Concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compared to amisulpride. Our data suggest that olanzapine is more efficacious than a number of other antipsychotic drugs in the longer term, but its efficacy must be weighed against its side effect profile.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
World Psychiatry
World Psychiatry Nursing-Psychiatric Mental Health
CiteScore
64.10
自引率
7.40%
发文量
124
期刊介绍: World Psychiatry is the official journal of the World Psychiatric Association. It aims to disseminate information on significant clinical, service, and research developments in the mental health field. World Psychiatry is published three times per year and is sent free of charge to psychiatrists.The recipient psychiatrists' names and addresses are provided by WPA member societies and sections.The language used in the journal is designed to be understandable by the majority of mental health professionals worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信